• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Alimera Sciences

edit

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Milestones

edit

• 
  Alimera Sciences added David Holland as senior VP of sales and marketing.
  Posted 8/18/10 at 6:23pm
• 
  Alimera Sciences added Richard Eiswirth, Jr as COO.
  Posted 8/18/10 at 6:23pm
• 
  Alimera Sciences added Ken Greene as Sr. Vice President & CSO .
  Posted 6/19/09 at 4:59am
• 
  Alimera Sciences added Rick Eiswirth as CFO.
  Posted 6/19/09 at 4:59am
• 
  Alimera Sciences added Susan Caballa as Sr. Vice President, Regulatory & Medical Affairs.
  Posted 6/19/09 at 4:59am
• 
  Alimera Sciences added Dan Myers as President and CEO.
  Posted 6/19/09 at 4:59am
• 
  Went public with stock symbol NASDAQ:ALIM. (4/21/10)
  Posted 7/2/10 at 12:18pm
• 
  Alimera Sciences received $31.8M in Series B funding. (11/30/05)
  Posted 7/1/10 at 6:05am via gabio.org
• 
  Alimera Sciences received $5M in Series C funding. (10/1/09)
  Posted 10/21/09 at 6:23pm via onbiovc.com
• 
  Alimera Sciences received $30M in Series C funding. (3/1/08)
  Posted 6/19/09 at 4:59am via alimerasciences.com

Videos

Screenshots

edit

Products

edit

Iluvien

edit

Stock Price

Sources

1. Alimera Sciences Secures $31.8 Million in Series B Financing (gabio.org) [edit]
2. Alimera Sciences Closes $30 Million In Series C Financing, Increasing Stake In Medidurâ„¢ FA (alimerasciences.com) [edit]
3. Alimera Sciences, Inc.: Series C $5M (onbiovc.com) [edit]